Magellan Financial AUM slumps $2.4B ahead of merger
Magellan Financial Group (ASX:MFG) has reported a sharp $2.4 billion decline in assets under management for the March quarter.

Finance journalist at Grafa with years of experience covering Asia-Pacific financial markets at S&P Global, Mortgage Ezy, and GMA Network.
Magellan Financial Group (ASX:MFG) has reported a sharp $2.4 billion decline in assets under management for the March quarter.
For decades, the global transition to renewable energy was a project of incrementalism — a slow-moving mosaic of carbon taxes, solar subsidies, and earnest international accords that often felt more aspirational than urgent.
Policy wonks argued over the nuances of the Inflation Reduction Act, while climate activists lamented the glacial pace of the "energy pivot."
Imricor Medical Systems (ASX:IMR) submitted its NorthStar 3D Mapping System for FDA clearance.
Greenvale Energy (ASX:GRV) announced an operational breakthrough at its flagship Alpha Torbanite Project.
The Australian government has welcomed a breakthrough two-week ceasefire in the Middle East.
Perenti (ASX:PRN) announced a 12-month contract extension for its subsidiary, Barminco, at the Duketon Operations.
The Australian Securities and Investments Commission has declared war on "super-charged" AI-driven fraud.
Virco (NASDAQ:VIRC), the domestic manufacturer and supplier of furniture and equipment for the education market, reported full-year financial results for the fiscal year ended January 31, 2026, characterized by steady annual earnings and a robust liquidity position.
Barrick Gold (NYSE:B) welcomed a decisive legal victory on April 8, 2026, as the Ontario Court of Appeal dismissed an appeal brought by a group of Tanzanian residents concerning alleged human rights incidents near the North Mara gold mine.
Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on small molecule therapies for cancer and immune disorders, reported its first-quarter 2026 financial results and provided a comprehensive update on its lead clinical programs on April 8, 2026.